Cellular Systems Core

蜂窝系统核心

基本信息

  • 批准号:
    10281359
  • 负责人:
  • 金额:
    $ 28.69万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-08-11 至 2026-07-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY/ABSTRACT – Resource Core 2: Cellular Systems Core Investigators in the Joint Biology Consortium (JBC) share a set of challenges that impede utilization of state-of- the-art technologies for research in arthritis and related diseases. Building on success in the first cycle of the JBC, the Cellular Systems Core (CSC) will leverage local resources and economies of scale to cultivate an integrated set of research tools to serve JBC members. The CSC will provide two broad categories of service. First, the CSC will deliver technologies realized through next-generation sequencing. These include single-cell RNAseq, ATAC-seq, T- and B-cell receptor sequencing, genomic DNA sequencing, spatial transcriptomics, CRISPR-based genomic perturbation screens, and autoantigen detection through PhIP-seq and T-scan. Second, the CSC will deliver tools centered on protein detection. These include optimized cytometry by time of flight (CyTOF), tissue mass cytometry, and Luminex-based screens for economical, customizable detection of cyctokines, antibodies, and other proteins. Resulting data will be analyzed through the new Joint Biology Consortium Bioinformatics Core, providing both high-end big-data analysis and structured education and coaching for JBC members, with the goal of developing a community of investigators conversant with advanced computational methods. This program integrates services available through the Brigham and Women’s Hospital Single-Cell Genomics Core and Center for Data Sciences, the Harvard Medical Area CyTOF Core, the Boston Children’s Hospital Division of Immunology, the Broad Institute’s Genomic Perturbation Platform, and other affiliated cores and labs. Progressive optimization of CSC services – now encompassing both cells and intact tissues – will result further through close affiliation with technical and computational leaders of the Accelerating Medicines Partnership (AMP) consortium in rheumatoid arthritis and lupus, ensuring JBC members access to the latest methodologic advances. Service delivery will be led by a scientific team consisting of Harvard CyTOF director Dr. James Lederer supported by associate directors Dr. Kevin Wei and bioinformatician Dr. Maria Gutierrez- Arcelus. This team will ensure that the logistical investment represented by the Cellular Systems Core continues to accelerate innovative translational arthritis research within the JBC.
项目摘要/摘要-资源核心2:蜂窝系统核心

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JAMES A. LEDERER其他文献

JAMES A. LEDERER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JAMES A. LEDERER', 18)}}的其他基金

Targeting Trained Immunity in Trauma-Induced Immune Dysregulation
针对创伤引起的免疫失调中训练有素的免疫力
  • 批准号:
    10714384
  • 财政年份:
    2023
  • 资助金额:
    $ 28.69万
  • 项目类别:
Adaptive Immune Regulation of Traumatic Injury
创伤性损伤的适应性免疫调节
  • 批准号:
    10415072
  • 财政年份:
    2020
  • 资助金额:
    $ 28.69万
  • 项目类别:
Adaptive Immune Regulation of Traumatic Injury
创伤性损伤的适应性免疫调节
  • 批准号:
    10186694
  • 财政年份:
    2020
  • 资助金额:
    $ 28.69万
  • 项目类别:
Adaptive Immune Regulation of Traumatic Injury
创伤性损伤的适应性免疫调节
  • 批准号:
    10624318
  • 财政年份:
    2020
  • 资助金额:
    $ 28.69万
  • 项目类别:
Therapy of acute radiation syndrome and its complications by mesenchymal stromal cells conditioned with Toll-like receptor 9 agonists
Toll样受体9激动剂诱导间充质基质细胞治疗急性放射综合征及其并发症
  • 批准号:
    9899920
  • 财政年份:
    2018
  • 资助金额:
    $ 28.69万
  • 项目类别:
Therapy of acute radiation syndrome and its complications by mesenchymal stromal cells conditioned with Toll-like receptor 9 agonists
Toll样受体9激动剂诱导间充质基质细胞治疗急性放射综合征及其并发症
  • 批准号:
    10374106
  • 财政年份:
    2018
  • 资助金额:
    $ 28.69万
  • 项目类别:
Cellular Systems Core
蜂窝系统核心
  • 批准号:
    10454989
  • 财政年份:
    2016
  • 资助金额:
    $ 28.69万
  • 项目类别:
Single Cell and Immunoanalysis Core
单细胞和免疫分析核心
  • 批准号:
    10455094
  • 财政年份:
    2016
  • 资助金额:
    $ 28.69万
  • 项目类别:
Single Cell and Immunoanalysis Core
单细胞和免疫分析核心
  • 批准号:
    10615219
  • 财政年份:
    2016
  • 资助金额:
    $ 28.69万
  • 项目类别:
Cellular Systems Core
蜂窝系统核心
  • 批准号:
    10684886
  • 财政年份:
    2016
  • 资助金额:
    $ 28.69万
  • 项目类别:

相似海外基金

Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
  • 批准号:
    24K16436
  • 财政年份:
    2024
  • 资助金额:
    $ 28.69万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
  • 批准号:
    10093543
  • 财政年份:
    2024
  • 资助金额:
    $ 28.69万
  • 项目类别:
    Collaborative R&D
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
  • 批准号:
    24K16488
  • 财政年份:
    2024
  • 资助金额:
    $ 28.69万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 28.69万
  • 项目类别:
    EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
  • 批准号:
    24K20973
  • 财政年份:
    2024
  • 资助金额:
    $ 28.69万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 28.69万
  • 项目类别:
    EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
  • 批准号:
    481560
  • 财政年份:
    2023
  • 资助金额:
    $ 28.69万
  • 项目类别:
    Operating Grants
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
  • 批准号:
    10075502
  • 财政年份:
    2023
  • 资助金额:
    $ 28.69万
  • 项目类别:
    Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
  • 批准号:
    10089082
  • 财政年份:
    2023
  • 资助金额:
    $ 28.69万
  • 项目类别:
    EU-Funded
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
  • 批准号:
    2321091
  • 财政年份:
    2023
  • 资助金额:
    $ 28.69万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了